VMI
ORKA

VHCP Management II’s Oruka Therapeutics ORKA Stock Holding History

VHCP Management II’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,995
Closed -$1.46M – 21
2017
Q4 		$1.46M Hold
4,995
– – 0.35% 17
2017
Q3 		$1.24M Hold
4,995
– – 0.34% 18
2017
Q2 		$2.59M Hold
4,995
– – 1.03% 12
2017
Q1 		$2.75M Hold
4,995
– – 1.13% 12
2016
Q4 		$3.08M Hold
4,995
– – 1.47% 15
2016
Q3 		$3.05M Hold
4,995
– – 1.57% 18
2016
Q2 		$3.13M Hold
4,995
– – 1.89% 15
2016
Q1 		$3.74M Hold
4,995
– – 2.46% 14
2015
Q4 		$5.02M Buy
+4,995
New +$5.66M 4.12% 10

Other funds holding ORKA

TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

VHCP Management II's ORKA Position: Q1 2018 in Review

VHCP Management II sold out of Oruka Therapeutics (ORKA) in Q1 2018, closing a stake of 4,995 shares — an estimated $1.46M sold.

VHCP Management II first reported a position in ORKA in Q4 2015 and held it in 9 quarters. The position peaked at $5.02M in Q4 2015. 16 funds tracked by Wall St. Rank hold ORKA as of Q1 2018.

  • VHCP Management II reported no remaining Oruka Therapeutics position as of Q1 2018 after selling out during the quarter.
  • VHCP Management II sold 4,995 Oruka Therapeutics shares in Q1 2018, an estimated $1.46M.
  • VHCP Management II first reported a position in Oruka Therapeutics in Q4 2015 and held it in 9 quarters.
  • VHCP Management II's Oruka Therapeutics position peaked at $5.02M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2018.

Based on VHCP Management II's 13F filing for Q1 2018, filed 14 May 2018.